Published in AIDS on September 01, 1996
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16
Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv (2010) 1.65
p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol (2003) 1.64
Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J Clin Microbiol (2002) 1.43
Detection and quantification of human immunodeficiency virus type 1 p24 antigen in dried whole blood and plasma on filter paper stored under various conditions. J Clin Microbiol (2005) 1.32
Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol (2005) 1.21
Comparison of an amplified enzyme-linked immunosorbent assay with procedures based on molecular biology for assessing human immunodeficiency virus type 1 viral load. Clin Diagn Lab Immunol (1998) 1.19
Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen. J Infect Dis (2010) 1.19
Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol (2005) 1.19
Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions. J Clin Microbiol (2004) 1.04
Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res (2011) 1.02
Potential of a simplified p24 assay for early diagnosis of infant human immunodeficiency virus type 1 infection in Haiti. J Clin Microbiol (2007) 1.01
Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection. Clin Vaccine Immunol (2010) 0.88
Circulating antibodies against Plasmodium falciparum histidine-rich proteins 2 interfere with antigen detection by rapid diagnostic tests. Malar J (2014) 0.87
Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virol J (2012) 0.84
Diagnostic accuracy of ultrasensitive heat-denatured HIV-1 p24 antigen in non-B subtypes in Kampala, Uganda. Int J STD AIDS (2011) 0.83
Diagnosis of human immunodeficiency virus type 1 infection in infants by immune complex dissociation p24 assay. Clin Diagn Lab Immunol (1997) 0.83
Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS One (2014) 0.79
Immunoliposome-PCR: a generic ultrasensitive quantitative antigen detection system. J Nanobiotechnology (2012) 0.79
Increased Sensitivity of HIV-1 p24 ELISA Using a Photochemical Signal Amplification System. J Acquir Immune Defic Syndr (2015) 0.78
Differences in humoral responses to the p24 antigen between Ethiopian and Swedish human immunodeficiency virus type 1-infected patients may suggest influences from a T-helper 2-like phenotype. Clin Diagn Lab Immunol (1997) 0.77
Potential of High-Affinity, Slow Off-Rate Modified Aptamer (SOMAmer) Reagents for Mycobacterium tuberculosis Proteins as Tools for Infection Models and Diagnostic Applications. J Clin Microbiol (2017) 0.76
Antigenemia in patients with mediterranean visceral leishmaniasis. J Clin Microbiol (2009) 0.75
Artificial 64-Residue HIV-1 Enhancer-Binding Peptide Is a Potent Inhibitor of Viral Replication in HIV-1-Infected Cells. Adv Virol (2011) 0.75
Establishment and Comparison of Two Different Diagnostic Platforms for Detection of DENV1 NS1 Protein. Int J Mol Sci (2015) 0.75
Impact of heat treatment on antigen detection in sera of Angiostrongylus vasorum infected dogs. Parasit Vectors (2017) 0.75
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
A method to identify protein sequences that fold into a known three-dimensional structure. Science (1991) 14.08
Profile analysis. Methods Enzymol (1990) 9.40
VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol (1997) 6.71
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med (1985) 2.95
Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology (2005) 2.69
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother (1985) 2.55
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed (1994) 2.38
Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother (1979) 2.29
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother (1985) 2.25
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev (1997) 2.21
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection. N Engl J Med (1997) 2.05
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med (1991) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc Natl Acad Sci U S A (1994) 1.84
Co-infection with human immunodeficiency virus-type 1 (HIV-1) and cytomegalovirus in two intravenous drug users. Ann Intern Med (1989) 1.82
A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell (1997) 1.80
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med (2012) 1.76
Progressive diffuse leukoencephalopathy in patients with acquired immune deficiency syndrome (AIDS). Acta Neuropathol (1985) 1.76
Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis (1998) 1.69
Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2000) 1.69
Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group. J Infect Dis (1994) 1.69
Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. J Infect Dis (1999) 1.58
Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol (1999) 1.53
Reasons for failure of prevention of Toxoplasma encephalitis. Swiss HIV Cohort Study. AIDS (1996) 1.52
Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma. AIDS (1997) 1.50
Rash with amoxycillin-clavulanate therapy in HIV-infected patients. Lancet (1989) 1.47
Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. J Infect Dis (2000) 1.41
False-positive HIV-1 virus cultures using whole blood. AIDS (1992) 1.40
[New developments and prospects of antiviral chemotherapy]. Internist (Berl) (1992) 1.39
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis (2016) 1.39
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods (1999) 1.36
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Arch Intern Med (1999) 1.28
Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA. J Med Virol (2001) 1.28
A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis (1991) 1.24
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses (1999) 1.22
Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis (1993) 1.21
Side-effects due to the intravenous infusion of erythromycin lactobionate. Infection (1983) 1.19
Biological variability of multiple dose pharmacokinetics of netilmicin in man. Eur J Clin Pharmacol (1983) 1.19
Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis (1994) 1.16
Quantitative and sensitive detection of immune-complexed and free HIV antigen after boiling of serum. J Virol Methods (1993) 1.14
Pulmonary and intestinal microsporidiosis in a patient with the acquired immunodeficiency syndrome. Am Rev Respir Dis (1992) 1.13
Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother (1987) 1.11
Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J Virol (1997) 1.11
Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses (2000) 1.10
Intestinal coinfection with Enterocytozoon bieneusi and Cryptosporidium in a human immunodeficiency virus-infected child with chronic diarrhea. Clin Infect Dis (1993) 1.07
Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. Int J Antimicrob Agents (2000) 1.07
Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol (1991) 1.04
Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol (2000) 1.03
Disseminated microsporidiosis due to Encephalitozoon hellem: pulmonary colonization, microhematuria, and mild conjunctivitis in a patient with AIDS. Clin Infect Dis (1993) 1.03
Frequent detection of HIV- and IgG-specific IgM and IgA antibodies in HIV-positive cord-blood sera: fine analysis by western blot. AIDS (1989) 1.03
Disseminated coinfection with Mycobacterium avium complex and Mycobacterium kansasii in a patient with AIDS and liver abscess. Clin Infect Dis (1992) 1.02
Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob Agents Chemother (1991) 1.01
Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr (1994) 1.00
Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother (1993) 1.00
Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother (1994) 0.99
[HIV-associated thrombocytopenia]. Schweiz Med Wochenschr (1988) 0.98
Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection (1993) 0.97
Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med (1992) 0.96
Regulation of neighboring gene expression by the herpes simplex virus type 1 thymidine kinase gene. Virology (1996) 0.96
Serological diagnosis of Q fever endocarditis. Eur Heart J (1986) 0.95
Enzyme-linked immunosorbent assay for diagnosis of chronic Q fever. J Clin Microbiol (1988) 0.95
A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care (2000) 0.95
Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. AIDS Res Hum Retroviruses (2010) 0.95
[On-line measurement of antibiotic concentrations (author's transl)]. Microsc Acta Suppl (1979) 0.94
Kaposi's sarcoma and malignant lymphoma in AIDS. Virchows Arch A Pathol Anat Histopathol (1984) 0.92
Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ (1990) 0.91
Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1995) 0.91
Ciprofloxacin-induced hematuria. Infection (1985) 0.90
Evaluation of diagnostic tests for HIV infection in infants born to HIV-infected mothers in Switzerland. AIDS (1988) 0.90
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2000) 0.90
Pregnancy, immunosuppression and reactivation of latent toxoplasmosis. J Perinat Med (1995) 0.89